Ken Masuda

Chuo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications

Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.

Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.

Journal: Journal for immunotherapy of cancer
Published: June 10, 2026

Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.

Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.

Journal: Anticancer research
Published: November 19, 2025

Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort study.

Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort study.

Journal: Translational lung cancer research
Published: November 10, 2025

Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples.

Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 03, 2025

Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer.

Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer.

Journal: British journal of cancer
Published: August 28, 2025

Exacerbation of cancer-associated retinopathy with anti-recoverin antibodies during atezolizumab treatment for extensive-stage small cell lung cancer: A case report.

Exacerbation of cancer-associated retinopathy with anti-recoverin antibodies during atezolizumab treatment for extensive-stage small cell lung cancer: A case report.

Journal: Respiratory investigation
Published: June 11, 2025

Effects of Sarcopenia on the Outcomes and Safety of Chemoradiotherapy Followed by Durvalumab for the Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer.

Effects of Sarcopenia on the Outcomes and Safety of Chemoradiotherapy Followed by Durvalumab for the Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer.

Journal: Thoracic cancer
Published: May 31, 2025

Determinants of human papillomavirus vaccination decision-making in Japan: a scoping review exploring contextual, social, and adolescent-specific influences.

Determinants of human papillomavirus vaccination decision-making in Japan: a scoping review exploring contextual, social, and adolescent-specific influences.

Journal: Vaccine
Published: May 06, 2025

Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.

Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 09, 2025

Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report.

Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report.

Journal: Thoracic cancer
Published: February 27, 2025

Impact of digital communication message on HPV vaccine decision-making among Japanese mothers: A randomized controlled trial.

Impact of digital communication message on HPV vaccine decision-making among Japanese mothers: A randomized controlled trial.

Journal: Vaccine
Published: February 12, 2025

Genetic Characteristics of Disease Flare After Lenvatinib Discontinuation in Patients With Thymic Carcinoma: A Brief Report.

Genetic Characteristics of Disease Flare After Lenvatinib Discontinuation in Patients With Thymic Carcinoma: A Brief Report.

Journal: JTO clinical and research reports
Published: January 15, 2025
Showing 1-12 of 78

Last Updated: 09/26/2026